Table 2.
Characteristics of proven/probable IFD.
| Type of IFD | Microbiology/Biomarker | |
|---|---|---|
|
Induction
(active hematologic disease) |
||
| 1 | Pulmonary aspergillosis | GM serum |
| 2 | Pulmonary aspergillosis | GM BAL |
| 3 | Pulmonary + sinus aspergillosis | GM serum |
| 4 | Pulmonary aspergillosis | A. terreus (BAL) |
| 5 | Pulmonary aspergillosis | GM serum |
| 6 | Pulmonary aspergillosis | GM serum/BAL |
| 7 | Geothricosis | S. capitata (lung biopsy) |
| 8 | Pulmonary aspergillosis | GM serum |
| 9 | Candidemia | Candida spp. |
| 10 | Candidemia | C. krusei |
| 11 | Candidemia | C. krusei + C. incospicua |
| 12 | Candidemia | C. glabrata |
|
Reinduction
(active hematologic disease) |
||
| 1 | Pulmonary aspergillosis | GM serum |
|
Consolidation
(controlled hematologic disease) |
||
| 1 | Pulmonary aspergillosis | GM serum |
| 2 | Pulmonary + sinus aspergillosis | GM BAL |
| 3 | Pulmonary aspergillosis | GM serum |
| 4 | Candidemia | C. parapsilosis |
IFD: invasive fungal disease; GM: galactomannan; BAL bronchoalveolar lavage.